<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372888</url>
  </required_header>
  <id_info>
    <org_study_id>20.205.01e</org_study_id>
    <nct_id>NCT04372888</nct_id>
  </id_info>
  <brief_title>Examining Choice Architecture for Genetic Testing Decisions</brief_title>
  <official_title>Examining Choice Architecture for Genetic Testing Decisions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this application is to gain a deeper understanding of decision-making for genetic&#xD;
      testing and identify effective choice-architecture-based strategies to improve decisions in&#xD;
      genetic testing. The investigators hypothesize that choice architecture (i.e. framing)&#xD;
      affects decision-making for hypothetical genetic testing scenarios.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After providing opt-in electronic consent, eligible consented participants will be randomized&#xD;
      to one of two hypothetical genetic testing scenarios (rare, life-altering genetic condition&#xD;
      or common, life-threatening genetic condition). The genetic testing scenarios include brief&#xD;
      detailed information about genetic testing (i.e. how results may influence treatment&#xD;
      decisions) as well as information about standard approaches to treatment. Subjects will be&#xD;
      randomized to receive a framing conditions (e.g. choice, opt-in, opt-out, enhanced choice).&#xD;
      Participants will select a preferred testing option to the hypothetical scenario and will&#xD;
      complete several validated instruments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Actual">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization to 1 of 6 decision frames for two disease testing scenarios (arms)</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>participants are blinded to arm and decision frame</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic testing decision</measure>
    <time_frame>after reading the scenario and viewing frame (approximately 10 minutes)</time_frame>
    <description>Opting &quot;yes&quot; for genetic testing or &quot;no&quot; refusing genetic testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction with Decision Scale (SWD)</measure>
    <time_frame>study completion (approximately 30 minutes)</time_frame>
    <description>SWD is a validated 6-item instrument, items are scored on a 1-5 scale with higher scores indicating greater satisfaction with the decision taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decisional Regret Scale (DRS)</measure>
    <time_frame>study completion (approximately 30 minutes)</time_frame>
    <description>DRS is a validated 5-item instrument, items are scored on a 1-5 scale with higher scores indicating more regret with the decision taken</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Newest Vital Sign (NVS)</measure>
    <time_frame>study completion (approximately 30 minutes)</time_frame>
    <description>NVS is a validated 6-item instrument, questions are based on reading and interpreting a food label, higher scores (more correct answers) indicate greater levels of literacy and numeracy abilities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experience with genetic disease</measure>
    <time_frame>Baseline (study onset)</time_frame>
    <description>Single &quot;yes&quot;/&quot;no&quot; question to determine a personal or family experience the genetic condition being presented in the scenario (arm)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1012</enrollment>
  <condition>Decision Making</condition>
  <arm_group>
    <arm_group_label>rare genetic disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hypothetical scenario 1: rare, life-altering genetic condition (congenital hypogonadotropic hypogonadism)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hypothetical scenario 2: common, life-threatening genetic condition (hereditary breast and ovarian cancer)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>choice decision frame</intervention_name>
    <description>active choice for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>opt-in decision frame</intervention_name>
    <description>&quot;gain&quot; frame for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>opt-out decision frame</intervention_name>
    <description>&quot;loss&quot; frame for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>enhanced choice (context) decision frame</intervention_name>
    <description>consequences of genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>enhanced choice (norms) decision frame</intervention_name>
    <description>social norms for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>enhanced choice (affect) decision frame</intervention_name>
    <description>commitments for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult participants (18-64 yrs) residing in North America (who are members of the&#xD;
             Amazon Mechanical Turk platform)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt;18yrs or &gt;65yrs or residing outside of North America&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew A Dwyer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston College</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02476</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mdpi.com/2073-4425/12/6/941</url>
    <description>link to full text article</description>
  </link>
  <results_reference>
    <citation>Dwyer AA, Shen H, Zeng Z, Gregas M, Zhao M. Framing Effects on Decision-Making for Diagnostic Genetic Testing: Results from a Randomized Trial. Genes (Basel). 2021 Jun 20;12(6). pii: 941. doi: 10.3390/genes12060941.</citation>
    <PMID>34202935</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

